Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TransMedics (TMDX) Accumulated Expenses (2018 - 2026)

TransMedics has reported Accumulated Expenses over the past 8 years, most recently at $28.4 million for Q4 2025.

  • For Q4 2025, Accumulated Expenses rose 26.28% year-over-year to $28.4 million; the TTM value through Dec 2025 reached $28.4 million, up 26.28%, while the annual FY2025 figure was $28.4 million, 26.28% up from the prior year.
  • Accumulated Expenses for Q4 2025 was $28.4 million at TransMedics, down from $56.0 million in the prior quarter.
  • Over five years, Accumulated Expenses peaked at $56.0 million in Q3 2025 and troughed at $2.7 million in Q3 2023.
  • A 5-year average of $19.2 million and a median of $16.4 million in 2021 define the central range for Accumulated Expenses.
  • Biggest five-year swings in Accumulated Expenses: crashed 66.5% in 2021 and later skyrocketed 673.98% in 2024.
  • Year by year, Accumulated Expenses stood at $16.3 million in 2021, then grew by 14.07% to $18.6 million in 2022, then rose by 8.93% to $20.3 million in 2023, then increased by 10.95% to $22.5 million in 2024, then rose by 26.28% to $28.4 million in 2025.
  • Business Quant data shows Accumulated Expenses for TMDX at $28.4 million in Q4 2025, $56.0 million in Q3 2025, and $42.5 million in Q2 2025.